MXPA02002436A - Metodo para el manejo terapeutico de la proliferacion extrauterina del tejido endometrial, dolor pelvico cronico y obstruccion de los tubos falopianos. - Google Patents

Metodo para el manejo terapeutico de la proliferacion extrauterina del tejido endometrial, dolor pelvico cronico y obstruccion de los tubos falopianos.

Info

Publication number
MXPA02002436A
MXPA02002436A MXPA02002436A MXPA02002436A MXPA02002436A MX PA02002436 A MXPA02002436 A MX PA02002436A MX PA02002436 A MXPA02002436 A MX PA02002436A MX PA02002436 A MXPA02002436 A MX PA02002436A MX PA02002436 A MXPA02002436 A MX PA02002436A
Authority
MX
Mexico
Prior art keywords
lhrh antagonist
short
treatment
induction treatment
administration
Prior art date
Application number
MXPA02002436A
Other languages
English (en)
Spanish (es)
Inventor
Jurgen Engel
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Publication of MXPA02002436A publication Critical patent/MXPA02002436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA02002436A 1999-09-23 2000-09-20 Metodo para el manejo terapeutico de la proliferacion extrauterina del tejido endometrial, dolor pelvico cronico y obstruccion de los tubos falopianos. MXPA02002436A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23
PCT/EP2000/009212 WO2001021194A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction

Publications (1)

Publication Number Publication Date
MXPA02002436A true MXPA02002436A (es) 2003-02-12

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002436A MXPA02002436A (es) 1999-09-23 2000-09-20 Metodo para el manejo terapeutico de la proliferacion extrauterina del tejido endometrial, dolor pelvico cronico y obstruccion de los tubos falopianos.

Country Status (22)

Country Link
EP (1) EP1214086A2 (enExample)
JP (2) JP2003509467A (enExample)
KR (1) KR100772852B1 (enExample)
CN (2) CN1376070A (enExample)
AU (1) AU769482B2 (enExample)
BG (1) BG66128B1 (enExample)
BR (1) BR0014198A (enExample)
CA (1) CA2383510A1 (enExample)
HK (1) HK1049117A1 (enExample)
HU (1) HUP0202741A3 (enExample)
IL (1) IL148185A0 (enExample)
MX (1) MXPA02002436A (enExample)
NO (1) NO331198B1 (enExample)
NZ (1) NZ534836A (enExample)
PL (1) PL201898B1 (enExample)
RU (1) RU2255759C2 (enExample)
SK (1) SK3752002A3 (enExample)
TR (1) TR200200738T2 (enExample)
TW (1) TWI267373B (enExample)
UA (1) UA73956C2 (enExample)
WO (1) WO2001021194A2 (enExample)
ZA (1) ZA200201374B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
PT2252627T (pt) 2008-01-24 2017-07-24 Esperance Pharmaceuticals Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos
WO2010085145A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
AU2013337926B2 (en) 2012-10-30 2017-12-21 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
EP3384930A1 (en) 2013-03-15 2018-10-10 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
CN111698992A (zh) 2017-08-18 2020-09-22 艾伯维公司 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物
WO2019036713A1 (en) 2017-08-18 2019-02-21 Abbvie Inc. SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
IL278082B2 (en) 2018-04-19 2025-03-01 Abbvie Inc Methods of treating heavy menstrual bleeding
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
FI970244L (fi) * 1994-07-22 1997-01-21 Hampton Roads Medical College Menetelmä vakiinnuttaa toonisen munasarjaestrogeenin erittyminen jatkettuja hoitotapoja varten
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
RU2108583C1 (ru) * 1996-07-29 1998-04-10 Николай Владимирович Рымашевский Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
AU729752B2 (en) * 1997-06-05 2001-02-08 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung

Also Published As

Publication number Publication date
RU2255759C2 (ru) 2005-07-10
TR200200738T2 (tr) 2002-08-21
WO2001021194A2 (en) 2001-03-29
HUP0202741A3 (en) 2003-12-29
HK1049117A1 (zh) 2003-05-02
TWI267373B (en) 2006-12-01
JP2012051920A (ja) 2012-03-15
SK3752002A3 (en) 2003-06-03
CN1376070A (zh) 2002-10-23
NO331198B1 (no) 2011-10-31
KR20020035879A (ko) 2002-05-15
EP1214086A2 (en) 2002-06-19
PL353244A1 (en) 2003-11-03
UA73956C2 (en) 2005-10-17
JP2003509467A (ja) 2003-03-11
BG66128B1 (bg) 2011-06-30
KR100772852B1 (ko) 2007-11-02
PL201898B1 (pl) 2009-05-29
WO2001021194A3 (en) 2002-03-14
IL148185A0 (en) 2002-09-12
AU7779200A (en) 2001-04-24
CA2383510A1 (en) 2001-03-29
AU769482B2 (en) 2004-01-29
CN101045155A (zh) 2007-10-03
HUP0202741A2 (hu) 2003-01-28
ZA200201374B (en) 2002-10-30
BR0014198A (pt) 2002-05-21
NZ534836A (en) 2007-07-27
NO20021430L (no) 2002-05-07
NO20021430D0 (no) 2002-03-21
BG106584A (bg) 2003-02-28

Similar Documents

Publication Publication Date Title
JP3130048B2 (ja) エストロゲン依存症の治療
JP2012051920A (ja) 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用
Erkkola et al. Role of progestins in contraception
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
TW577735B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
Bedaiwy et al. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists
US20080255053A1 (en) Method for the therapeutic management of endometriosis
BG106442A (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
US6689768B2 (en) Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy
JP3925688B2 (ja) ＧｎＲＨａ治療中および／またはＧｎＲＨａ治療後の副作用を治療するための製薬学的調剤
EP3784346A1 (en) A composition for treating one or more estrogen related diseases
US6106805A (en) Diagnostic composition containing an LH-RH antagonist for hysteroscopy
HK1107262A (en) Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
US20020002153A1 (en) Pharmaceutical preparations for treating side effects during and/or after gnrha therapy
US20040167111A1 (en) Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy
Swahn et al. Various uses of mifepristone in gynaecology and obstetrics
Patel 6 Hysteroscopic Implications
JP2007197459A (ja) 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration